Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
20.85
-0.18 (-0.86%)
At close: Feb 6, 2026, 4:00 PM EST
21.39
+0.54 (2.59%)
After-hours: Feb 6, 2026, 6:41 PM EST
Nanobiotix Employees
Nanobiotix had 103 employees as of June 30, 2025. The number of employees decreased by 5 or -4.63% since the number was reported on December 31, 2024.
Employees
103
Change
-5
Growth
-4.63%
Revenue / Employee
$115,832
Profits / Employee
-$588,830
Market Cap
1.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 103 | -5 | -4.63% | 103 | 0 |
| Dec 31, 2024 | 108 | 6 | 5.88% | 108 | 0 |
| Dec 31, 2023 | 102 | 0 | - | 102 | 0 |
| Dec 31, 2022 | 102 | 2 | 2.00% | 102 | 0 |
| Dec 31, 2021 | 100 | 10 | 11.11% | 100 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 838 |
| Phathom Pharmaceuticals | 427 |
| Vir Biotechnology | 408 |
| Sana Biotechnology | 194 |
| ARS Pharmaceuticals | 167 |
| EyePoint | 165 |
| ORIC Pharmaceuticals | 106 |
| MoonLake Immunotherapeutics | 100 |
NBTX News
- 25 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 7 weeks ago - NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris - GlobeNewsWire
- 2 months ago - Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations - GlobeNewsWire
- 3 months ago - NANOBIOTIX to Participate in Investor Conferences the Week of November 10th - GlobeNewsWire
- 3 months ago - NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth - GlobeNewsWire
- 4 months ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 4 months ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire